Activity Overview
This online, on-demand virtual symposium brings together renowned experts in KRAS mutations in solid tumors. In this educational program, these experts discuss key KRAS-related data presented at the 2026 ASCO Annual Meeting. Using a dynamic format that combines abstract presentations with expert faculty discussion, the program places emerging evidence into clinical context and explores its practical implications for treatment selection, toxicity management, and multidisciplinary care across multiple KRAS-mutated solid tumors. This approach helps clinicians translate new research findings into evidence-based strategies that can improve patient outcomes in everyday practice.
This educational activity is an archive of the live symposium held on July 30, 2026.
Target Audience
This educational activity is directed toward academic and community-based oncologists, pathologists, advanced practice providers, oncology nurses, and other health care providers involved in treating patients with KRAS/RAS-mutated cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the role of KRAS/RAS mutations across solid tumors and their implications for biomarker testing
- Assess efficacy and safety profiles of approved and emerging KRAS/RAS-targeted therapies in solid tumors
- Implement evidence-based strategies to prevent, monitor, and manage adverse events associated with KRAS/RAS-targeted therapies
Rajwanth Veluswamy, MD, MSCR
Associate Professor of Medicine
Thoracic Oncology
Co-Director, KRAS Excellence Initiative (KRAS-X)
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY
Disclosures: Advisor, Consultant, Fee for Service Recipient: Archetype Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, Merck, Merus, Novocure, Pfizer, Regeneron, Revolution Medicines, Serna Bio, Shionogi; Speakers Bureau: AbbVie, AstraZeneca; Grant/Research Funding: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lung Cancer Research Foundation, Onconova, Stand Up 2 Cancer, Tempus
Alison Schram, MD
Assistant Attending Physician
Section Head of Oral Therapeutics, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Fee for Service Recipient: Axiom Healthcare, Blueprint Bio, Boehringer Ingelheim, Day One Biopharmaceuticals, Endeavor Biomedicines, Guardant, Mersana, Merus, Partner Therapeutics, PMV Pharma, Redona Therapeutics, Relay Therapeutics, Repare Therapeutics, Revolution Medicines, Schrodinger, TransCode Therapeutics, Tubulis; Speaker Bureau: Axiom; Grant/Research Funding (to institution): ArQule, AstraZeneca, BeiGene/SpringWorks, Black Diamond Therapeutics, Boehringer Ingelheim, Debiopharm, Elevar Therapeutics, Elevation Oncology, Kura, Lilly, Merus, Northern Biologics, Partner Therapeutics, Pfizer, Pheon Therapeutics, PMV Pharma, Relay, Repare Therapeutics, Revolution Medicines, Surface Oncology; Steering Committee: Merus, Pfizer, Relay Therapeutics; Food and Beverage: Boehringer Ingelheim, Partner Therapeutics, Puma, Repare Therapeutics, Revolution Medicines
Brian M. Wolpin, MD, MPH
Professor of Medicine, Harvard Medical School
Robert T. and Judith B. Hale Chair in Pancreatic Cancer
Director, Gastrointestinal Cancer Center
Director, Hale Family Center for Pancreatic Cancer Research
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Agenus, BeiGene, Cancer Panels, EcoR1 Capital, GRAIL, Harbinger Health, Immuneering Corporation, Ipsen, Lustgarten Foundation, Mirati/Bristol Myers Squibb, Revolution Medicines, SystImmune, Takeda, TD Securities Tango Therapeutics, (TD Cowen), Third Rock Ventures; Grant/Research Funding: Agios, Amgen, AstraZeneca, Break Through Cancer, Eli Lilly, Harbinger Health, Lustgarten Foundation, The Mark Foundation for Cancer Research LTD, NIH/NCI, Novartis, Pancreatic Cancer Action Network, Revolution Medicines, Stand Up to Cancer, Stephenson Global Pancreatic Cancer Research Institute
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
